Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 10,043 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 10,043 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $28.10, for a total value of $282,208.30. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,744,588.50. This trade represents a 13.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $28.71 on Thursday. The firm has a market capitalization of $4.19 billion, a PE ratio of -15.69 and a beta of 1.55. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $30.58. The business’s 50-day moving average price is $25.05 and its 200-day moving average price is $24.54.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNTA. Campbell & CO Investment Adviser LLC bought a new stake in shares of Centessa Pharmaceuticals in the second quarter worth about $218,000. American Century Companies Inc. grew its position in shares of Centessa Pharmaceuticals by 3.5% in the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock worth $14,858,000 after buying an additional 37,954 shares during the last quarter. Eagle Health Investments LP purchased a new position in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $2,500,000. Royce & Associates LP bought a new position in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $5,999,000. Finally, Federated Hermes Inc. bought a new position in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $42,429,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Wolfe Research began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. B. Riley Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $39.80.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.